IndustryCompany release

Adial Pharmaceuticals renames itself Azora Therapeutics as ulcerative colitis drug AT177 heads for 2027 trial

🇺🇸 Adial Pharmaceuticals, Inc. (ADIL) · Wed 28 Oct 2026

The Nasdaq-listed company will trade as AZR from 29 October, with a new executive team and an oral AhR agonist expected to enter Phase 1 in the first half of 2027.

Adial Pharmaceuticals has changed its name to Azora Therapeutics, effective 28 October 2026. Its shares will trade on Nasdaq under the ticker AZR from 29 October.

Stockholders approved the conversion of Series A preferred stock that was issued in connection with the company's June 2026 acquisition of Azora. A new executive team has also been appointed, though the summary available does not give names or roles.

The lead asset is AT177, an oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for ulcerative colitis. It is currently in IND-enabling studies, the preclinical work that typically supports an investigational new drug application to the US Food and Drug Administration.

The company expects to start a Phase 1 trial in the first half of 2027. It projects that its cash will last into 2028, which would cover the planned move into the clinic.

What it means for your team

  • Regulatory teams tracking AT177 should expect an IND filing before the planned Phase 1 start in the first half of 2027.
  • Anyone maintaining company or product records should update the name to Azora Therapeutics and the Nasdaq ticker to AZR from 29 October 2026.
  • Market-access and competitive-intelligence teams in ulcerative colitis can note a new oral, colon-targeted AhR agonist entering the pipeline, still at a preclinical stage.
  • The cash runway into 2028 is the company's own projection and depends on development progress.

Company's press release (SEC filing): Adial Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Adial Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →